Key Insights

Highlights

Treatment Research

13 treatments under study, led by Pd1 Inhibitor Monotherapy 2 Cycles Before 1200pm

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Recruiting2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07630168Phase 2Recruiting

Effects of Infusion Timing on Treatment Response in Solid Tumors

NCT06997094Phase 1Recruiting

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

NCT06235918Phase 2Unknown

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Showing all 3 trials

Research Network

Common Treatments

  • Pd1 Inhibitor Monotherapy 2 Cycles Before 1200pm1
  • Chemotherapy1
  • Pd1pdl1 Inhibitor Monotherapy 4 Cycles Before 1200pm1
  • Biospecimen Collection1
  • Nabpaclitaxel1

Active Sponsors

  • UNC Lineberger Comprehensive Cancer Center1
  • Mayo Clinic1
  • Xiang Lu1

Top Investigators

Related Conditions

  • Lung Cancer1
  • Nonsmall Cell Lung Cancer1
  • Resectable Head And Neck Squamous Cell Carcinoma1
  • Head And Neck Cancer1
  • Hpvnegative Squamous Cell Carcinoma1

Activity Timeline